Marshall Wace LLP Boosts Stock Holdings in Johnson & Johnson $JNJ

Marshall Wace LLP lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 73.5% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 1,583,553 shares of the company’s stock after purchasing an additional 670,669 shares during the period. Marshall Wace LLP owned about 0.07% of Johnson & Johnson worth $241,888,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of JNJ. Brighton Jones LLC lifted its stake in shares of Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after purchasing an additional 6,332 shares during the last quarter. Smart Money Group LLC raised its holdings in Johnson & Johnson by 6.5% in the first quarter. Smart Money Group LLC now owns 6,687 shares of the company’s stock worth $1,109,000 after purchasing an additional 407 shares in the last quarter. United Bank lifted its position in shares of Johnson & Johnson by 110.7% during the first quarter. United Bank now owns 9,279 shares of the company’s stock valued at $1,539,000 after buying an additional 4,876 shares during the last quarter. WealthShield Partners LLC boosted its holdings in shares of Johnson & Johnson by 9.2% in the 1st quarter. WealthShield Partners LLC now owns 5,980 shares of the company’s stock valued at $992,000 after buying an additional 505 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Johnson & Johnson by 3.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 18,899,263 shares of the company’s stock worth $3,133,602,000 after buying an additional 712,181 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

JNJ has been the topic of several analyst reports. Daiwa America raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Monday, October 20th. Barclays increased their price target on Johnson & Johnson from $176.00 to $197.00 and gave the company an “equal weight” rating in a research note on Tuesday. JPMorgan Chase & Co. boosted their price target on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 16th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $209.00 price objective on shares of Johnson & Johnson in a research report on Friday, October 10th. Finally, Loop Capital set a $190.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 22nd. Four equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $202.10.

Johnson & Johnson Trading Down 1.5%

Johnson & Johnson stock opened at $202.24 on Friday. The stock has a 50-day moving average price of $193.61 and a 200 day moving average price of $174.90. The company has a market capitalization of $487.25 billion, a price-to-earnings ratio of 19.52, a price-to-earnings-growth ratio of 2.29 and a beta of 0.36. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $207.81. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.6%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.